News | March 21, 2011

OrbusNeich Files Lawsuit Over Stent Clinical Trial Results

March 21, 2011 - OrbusNeich today announced it filed a lawsuit in the Netherlands against a doctor and principal investigator of a trial examining OrbusNeich's Genous coronary stent. The results of the study reported adverse events with the stent, but a review of the study by OrbusNeich and independent evaluators showed the study contained many inaccuracies, misrepresentations and inconsistencies.

The suit names Dr. Pavel Cervinka and Masaryk Hospital in Usti nad Labem, Czech Republic, where Cervinka is head of the hospital's cardiology department. The suit relates to a clinical study conducted at the Masaryk Hospital, which randomly compared the Genous stent with a bare metal stent for treatment of heart attack patients.

The lawsuit alleges Cervinka and the Masaryk Hospital have committed unlawful acts and asks for an injunction against further presentations or publications of the study. OrbusNeich also requests that the court's decision be submitted for publication in the U.S. journal in which the study was published by Cervinka and an acknowledgement of the decision also be placed by Cervinka in the journal.

After the first presentation of the study at the American College of Cardiology (ACC) in March 2009, OrbusNeich contacted Cervinka to discuss the study and investigate the circumstances surrounding the reported adverse events. In response, Cervinka provided limited information on three patients who experienced a stent thrombosis (blood clot). The company said an independent evaluation of the data relating to those patients revealed procedural complications for all three patients, namely under-expansion of the stent, geographic miss and malapposed struts in a jailed diagonal branch. The company said all these factors are recognized risk factors for stent thrombosis. It also revealed discrepancies in the reported data and inconsistencies and misrepresentations in the study and the reporting of the study.

Upon presentation of the findings of the independent evaluation, Cervinka admitted that he had made mistakes. However, changes that he made to subsequent presentations and the publication of the study in a medical journal did not correct the reporting of the defects in the study, nor admit nor publish the errors and invalidity of the study, the company claims.

Cervinka presented the results and conclusions of the study a number of times after he and the Masaryk Hospital were made aware of the defects in the study and the study reporting. As a result of the wide dissemination of the study, numerous clinicians stopped using the product and terminated clinical trials, and OrbusNeich suffered reputational damage, the company claims.

For more information: www.OrbusNeich.com

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Overlay Init